Certara, Inc. (NASDAQ:CERT) Shares Acquired by Sei Investments Co.

Sei Investments Co. increased its stake in shares of Certara, Inc. (NASDAQ:CERT) by 39.5% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 997,871 shares of the company’s stock after purchasing an additional 282,357 shares during the period. Sei Investments Co. owned 0.62% of Certara worth $13,821,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Norges Bank purchased a new stake in Certara during the 4th quarter worth approximately $14,262,000. Evoke Wealth LLC purchased a new stake in shares of Certara during the fourth quarter worth approximately $1,723,000. Premier Fund Managers Ltd raised its stake in Certara by 87.5% in the 4th quarter. Premier Fund Managers Ltd now owns 16,553 shares of the company’s stock valued at $296,000 after purchasing an additional 7,727 shares during the last quarter. Scout Investments Inc. lifted its holdings in Certara by 18.9% in the 4th quarter. Scout Investments Inc. now owns 368,790 shares of the company’s stock valued at $6,487,000 after purchasing an additional 58,746 shares in the last quarter. Finally, Wasatch Advisors LP lifted its holdings in Certara by 22.7% in the 4th quarter. Wasatch Advisors LP now owns 3,992,247 shares of the company’s stock valued at $70,224,000 after purchasing an additional 737,982 shares in the last quarter. 73.96% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Certara news, insider Leif E. Pedersen sold 51,224 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $11.29, for a total value of $578,318.96. Following the sale, the insider now owns 99,704 shares of the company’s stock, valued at $1,125,658.16. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 2.39% of the stock is currently owned by corporate insiders.

Certara Price Performance

NASDAQ:CERT opened at $11.75 on Friday. Certara, Inc. has a 52 week low of $10.35 and a 52 week high of $19.87. The stock’s fifty day moving average is $12.73 and its two-hundred day moving average is $15.11. The company has a market capitalization of $1.89 billion, a P/E ratio of -30.13, a P/E/G ratio of 5.17 and a beta of 1.49. The company has a quick ratio of 2.61, a current ratio of 2.61 and a debt-to-equity ratio of 0.28.

Certara (NASDAQ:CERT) last announced its earnings results on Tuesday, August 6th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.03). Certara had a positive return on equity of 3.03% and a negative net margin of 21.64%. The company had revenue of $93.31 million for the quarter, compared to analysts’ expectations of $96.01 million. During the same period last year, the business earned $0.10 EPS. The company’s quarterly revenue was up 3.2% compared to the same quarter last year. Equities analysts expect that Certara, Inc. will post 0.27 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on CERT shares. JMP Securities reaffirmed a “market perform” rating on shares of Certara in a report on Wednesday, July 10th. UBS Group upgraded shares of Certara from a “neutral” rating to a “buy” rating and set a $16.00 price objective for the company in a report on Friday. Robert W. Baird lowered their target price on Certara from $19.00 to $18.00 and set a “neutral” rating on the stock in a report on Wednesday, August 7th. KeyCorp dropped their price target on Certara from $23.00 to $20.00 and set an “overweight” rating for the company in a research report on Thursday, July 11th. Finally, Barclays reduced their price objective on Certara from $18.00 to $16.00 and set an “equal weight” rating on the stock in a research report on Friday, June 28th. Six research analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $17.79.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.